Compare · CCXI vs PRE
CCXI vs PRE
Side-by-side comparison of Churchill Capital Corp XI (CCXI) and Prenetics Global Limited (PRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCXI and PRE operate in Blank Checks (Finance), so they compete in similar markets.
- PRE carries a market cap of $276.6M.
- Over the past year, CCXI is up 8.8% and PRE is up 33.6% - PRE leads by 24.8 points.
- CCXI has been more active in the news (40 items in the past 4 weeks vs 9 for PRE).
- Both have 8 recent analyst ratings on file.
Churchill Capital Corp XI
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
Latest CCXI
- Chief Operating Officer Hunter Jennifer was granted 3,220,699 stock options (SEC Form 4)
- Officer Lang Anastasia was granted 2,760,599 stock options (SEC Form 4)
- Director Shelton Damion was granted 9,938,151 shares (SEC Form 4)
- Chief Technology Officer Velagapudi Prasanna was granted 3,680,797 stock options (SEC Form 4)
- Chief Financial Officer Beer Michael Thomas was granted 2,576,560 shares (SEC Form 4)
- Chief Executive Officer Johnson Margaret L was granted 347,790 shares (SEC Form 4)
- Chief Robot Officer Hurst Jonathan was granted 12,422,709 shares (SEC Form 4)
- Chief Hardware Officer Marroquin Marco was granted 2,300,498 stock options (SEC Form 4)
- President Diez Daniel was granted 3,220,699 stock options (SEC Form 4)
- SEC Form 3 filed by new insider Hunter Jennifer
Latest PRE
- SEC Form 6-K filed by Prenetics Global Limited
- Prenetics’ IM8 Announces Three-Time GRAMMY-Winning DJ and Producer Diplo as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
- Director Leogrande Hudson Blake converted options into 2,000 units of Class A Ordinary Share, increasing direct ownership by 25% to 10,001 units (SEC Form 4)
- SEC Form 6-K filed by Prenetics Global Limited
- Care Bears And Prenetics' IM8 Announce Global Partnership
- SEC Form 6-K filed by Prenetics Global Limited
- Prenetics’ IM8 Names Brian J. Rosin as Successor Chief Financial Officer
- SEC Form 6-K filed by Prenetics Global Limited
- Maxim Group initiated coverage on Prenetics Group Ltd. with a new price target
- SEC Form 6-K filed by Prenetics Global Limited